PetIQ, Inc. (PETQ)
USD 30.98
(-0.03%)
USD 30.98
(-0.03%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 351.93 Million USD | -5.05% |
| 2022 | 370.66 Million USD | -7.62% |
| 2021 | 401.25 Million USD | 13.24% |
| 2020 | 354.32 Million USD | 40.35% |
| 2019 | 252.45 Million USD | 453.29% |
| 2018 | 45.62 Million USD | 326.18% |
| 2017 | -20.17 Million USD | -174.31% |
| 2016 | 27.14 Million USD | -7.51% |
| 2015 | 29.35 Million USD | 115.49% |
| 2014 | 13.62 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 376.45 Million USD | -14.28% |
| 2024 Q1 | 439.14 Million USD | 24.78% |
| 2023 Q4 | 351.93 Million USD | 3.82% |
| 2023 Q1 | 443.27 Million USD | 19.59% |
| 2023 Q2 | 387.3 Million USD | -12.63% |
| 2023 Q3 | 338.97 Million USD | -12.48% |
| 2023 FY | 351.93 Million USD | -5.05% |
| 2022 Q4 | 370.66 Million USD | -11.35% |
| 2022 FY | 370.66 Million USD | -7.62% |
| 2022 Q1 | 452.76 Million USD | 12.84% |
| 2022 Q2 | 477.37 Million USD | 5.44% |
| 2022 Q3 | 418.12 Million USD | -12.41% |
| 2021 FY | 401.25 Million USD | 13.24% |
| 2021 Q3 | 406.85 Million USD | -11.58% |
| 2021 Q4 | 401.25 Million USD | -1.38% |
| 2021 Q2 | 460.14 Million USD | -0.56% |
| 2021 Q1 | 462.72 Million USD | 30.59% |
| 2020 Q1 | 325.44 Million USD | 28.91% |
| 2020 Q4 | 354.32 Million USD | 7.77% |
| 2020 Q3 | 328.76 Million USD | 22.8% |
| 2020 Q2 | 267.73 Million USD | -17.73% |
| 2020 FY | 354.32 Million USD | 40.35% |
| 2019 Q4 | 252.45 Million USD | -7.18% |
| 2019 FY | 252.45 Million USD | 453.29% |
| 2019 Q1 | 75.32 Million USD | 65.09% |
| 2019 Q2 | 79.46 Million USD | 5.49% |
| 2019 Q3 | 271.97 Million USD | 242.26% |
| 2018 Q4 | 45.62 Million USD | -59.86% |
| 2018 FY | 45.62 Million USD | 326.18% |
| 2018 Q1 | 135.96 Million USD | 773.99% |
| 2018 Q2 | 106.91 Million USD | -21.37% |
| 2018 Q3 | 113.65 Million USD | 6.31% |
| 2017 Q3 | -26.06 Million USD | -174.6% |
| 2017 Q2 | 34.93 Million USD | -21.61% |
| 2017 Q1 | 44.56 Million USD | 64.18% |
| 2017 FY | -20.17 Million USD | -174.31% |
| 2017 Q4 | -20.17 Million USD | 22.59% |
| 2016 FY | 27.14 Million USD | -7.51% |
| 2016 Q4 | 27.14 Million USD | 0.0% |
| 2016 Q1 | 27.4 Million USD | 0.0% |
| 2015 Q1 | 1.37 Million USD | 0.0% |
| 2015 FY | 29.35 Million USD | 115.49% |
| 2014 FY | 13.62 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | -273.574% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | -369.557% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 19.158% |
| Cosmos Health Inc. | 8.59 Million USD | -3996.647% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 4384.824% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 23.276% |
| Cronos Group Inc. | -663.32 Million USD | 153.056% |
| Incannex Healthcare Limited | -5.48 Million USD | 6516.281% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 2515.132% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | -188.711% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 12229.648% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 2350.982% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 2350.982% |
| SCYNEXIS, Inc. | -19.35 Million USD | 1918.775% |
| Safety Shot Inc | -2.28 Million USD | 15506.096% |
| Theratechnologies Inc. | 24.87 Million USD | -1315.034% |
| Alpha Teknova, Inc. | 1.97 Million USD | -17728.419% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -178356.866% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 18.674% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 14065.595% |
| Dynavax Technologies Corporation | 106.63 Million USD | -230.035% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 43.545% |
| Radius Health, Inc. | 359.28 Million USD | 2.045% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 3832.163% |
| Alvotech | 1.06 Billion USD | 66.933% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 369.002% |
| SIGA Technologies, Inc. | -148.68 Million USD | 336.702% |
| Shineco, Inc. | 29.29 Million USD | -1101.534% |
| Silver Spike Investment Corp. | -32.61 Million USD | 1179.164% |
| Journey Medical Corporation | -9.7 Million USD | 3724.812% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 7054.67% |
| Embecta Corp. | 1.31 Billion USD | 73.176% |
| Harrow Health, Inc. | 116.41 Million USD | -202.304% |
| Procaps Group, S.A. | 242.93 Million USD | -44.869% |
| Biofrontera Inc. | 4.05 Million USD | -8576.849% |
| DURECT Corporation | -7.65 Million USD | 4698.027% |
| PainReform Ltd. | -7.95 Million USD | 4526.83% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 1149.7% |
| OptiNose, Inc. | 58.06 Million USD | -506.102% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 6886.172% |
| Organogenesis Holdings Inc. | 15.01 Million USD | -2244.188% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -329243.34% |
| ProPhase Labs, Inc. | 19.23 Million USD | -1730.03% |
| Phibro Animal Health Corporation | 454.84 Million USD | 22.626% |
| Procaps Group S.A. | 242.93 Million USD | -44.869% |
| TherapeuticsMD, Inc. | 3.67 Million USD | -9468.597% |
| Viatris Inc. | 17.13 Billion USD | 97.946% |
| Rockwell Medical, Inc. | 4.45 Million USD | -7797.958% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 7316.178% |
| Tilray Brands, Inc. | 158.97 Million USD | -121.374% |
| Talphera, Inc. | -5.72 Million USD | 6251.599% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -98.496% |
| Alimera Sciences, Inc. | 55.3 Million USD | -536.303% |
| Assertio Holdings, Inc. | -32.52 Million USD | 1181.905% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 23739.941% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | -8245.577% |
| Hempacco Co., Inc. | 13.61 Million USD | -2484.952% |
| Alvotech | 1.06 Billion USD | 66.933% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 463.905% |
| Kamada Ltd. | -46.43 Million USD | 857.961% |
| Currenc Group, Inc. | -16.57 Million USD | 2223.516% |
| Indivior PLC | -33.95 Million USD | 1136.561% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -134960.674% |
| Flora Growth Corp. | -713 Thousand USD | 49459.467% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 4384.824% |
| Evolus, Inc. | 63.7 Million USD | -452.416% |
| HUTCHMED (China) Limited | -197.45 Million USD | 278.232% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 26.545% |
| Akanda Corp. | 3.9 Million USD | -8912.563% |